Trial Watch No. 17
The Largest mRNA Vaccine Efficacy Trial Ever Registered
Where conviction is building in clinical development, in real time. GSK opened a 54,000-patient Phase 3 of an mRNA seasonal influenza vaccine in adults 65+, Eli Lilly extended the obesity and T2D franchise across three new age brackets, and gene editing platforms diversified beyond monogenic disease.
Summary Layer
The first half of September 2026 delivers the largest mRNA-vaccine efficacy trial ever registered. GSK opened a 54,000-patient Phase 3 of an mRNA-based seasonal influenza vaccine in adults 65+, compared head-to-head against licensed influenza vaccines. This is the definitive readout for the mRNA-vs-legacy-flu-vaccine question; a franchise-scale bet parallel to Moderna's and Pfizer's own mRNA flu programs.
Eli Lilly extends the obesity/T2D franchise across three new age brackets in a single window: Orforglipron in overweight (2,001 pts) targeting the pre-obesity population, Orforglipron in pediatric T2D age 10 to 18 (170 pts, 71 sites), and Tirzepatide in pediatric obesity age 6 to 12 (150 pts, 84 sites). Lilly is reframing metabolic disease from adult treatment to lifelong risk reduction.
Gene editing platforms diversify beyond monogenic disease. Prime Medicine opened its first Prime Editing Phase 1/2 in Wilson Disease (PM577a). CRISPR Therapeutics opened CTX112; allogeneic CRISPR-Cas9-engineered CD19 CAR-T for refractory neurologic autoimmune disease (MS, NMO, MOG-AD, autoimmune encephalitis, stiff-person syndrome). Both platforms now have Phase 1/2 clinical proof-of-concept trials in the same 2-week window. 15 high-signal trials across oncology, cardiometabolic, immunology, vaccines, and advanced modalities.
Therapeutic Areas Covered
Oncology
5 trialsTrastuzumab Rezetecan (SHR-A1811) + Adebrelimab vs. Investigator's Choice in TNBC With Residual Invasive Disease After Neoadjuvant Therapy
Phase 3 · Oncology; residual TNBC (post-neoadjuvant); MEGA-SCALE
Timeline
Start September 2, 2026; Primary completion December 2030
Mechanism
Trastuzumab Rezetecan (SHR-A1811) is Hengrui's HER2-directed ADC with a topoisomerase I payload (structurally analogous to trastuzumab deruxtecan). Combined with adebrelimab (SHR-1316, Hengrui's anti-PD-L1) in TNBC patients with residual invasive disease after neoadjuvant therapy; vs. capecitabine or pembrolizumab investigator's choice.
Why It Matters
Trastuzumab deruxtecan (Enhertu) has redefined HER2-low breast cancer. SHR-A1811 is China's most advanced HER2 ADC challenger; this 1,000-patient Phase 3 in TNBC residual disease positions Hengrui to compete directly with the AstraZeneca/Daiichi Sankyo Enhertu franchise. Positive readout establishes Hengrui as a global HER2 ADC contender.
Verified sources
TiTan · Teclistamab + Talquetamab vs. Daratumumab + Lenalidomide in MRD-Positive NDMM Post-ASCT
Phase 3 · Oncology; MRD+ NDMM post-ASCT; dual-BiTE combo
Timeline
Start September 2026; Primary completion June 2031
Mechanism
First randomized Phase 3 of two Janssen bispecific antibodies in combination; Teclistamab (BCMAxCD3) + Talquetamab (GPRC5DxCD3); vs. the current post-ASCT maintenance standard of subcutaneous daratumumab + lenalidomide in MRD-positive newly diagnosed multiple myeloma patients after autologous stem cell transplant.
Why It Matters
BiTE-on-BiTE combinations reach Phase 3 for the first time in NDMM. If TiTan wins, MRD+ post-ASCT patients get access to dual-antigen bispecific consolidation; a fundamentally different post-transplant paradigm than the current daratumumab + lenalidomide standard. Validates dual-BiTE combination therapy as a Phase 3 strategy across hematologic malignancies.
Verified sources
EXCALIBUR-ET2 · INCA033989 vs. Best Available Therapy in Cytoreductive-Treated CALR-Mutant Essential Thrombocythemia
Phase 3 · Oncology; CALR+ essential thrombocythemia
Timeline
Start September 8, 2026; Primary completion June 2029
Mechanism
INCA033989 is Incyte's first-in-class monoclonal antibody selectively targeting mutant CALR (calreticulin) protein on the surface of CALR-mutant myeloproliferative neoplasm cells. Tested vs. best available therapy (hydroxyurea, anagrelide, interferon) in ET patients previously treated with cytoreductive therapy.
Why It Matters
First Phase 3 of a mutant-CALR-targeted therapy in any indication. CALR mutations drive ~25 to 30% of essential thrombocythemia and ~30% of primary myelofibrosis; historically undruggable because CALR is intracellular. Targeting the mutant protein on the cell surface is a first-in-class approach. Positive readout would open a new therapeutic category across MPNs.
Verified sources
ATG-022 vs. Investigator's Choice in CLDN18.2-Positive Advanced Gastric or GEJ Adenocarcinoma
Phase 3 · Oncology; CLDN18.2+ gastric/GEJ
Timeline
Start September 1, 2026; Primary completion December 2029
Mechanism
ATG-022 is Antengene's CLDN18.2-directed antibody-drug conjugate for advanced gastric/GEJ adenocarcinoma. Tested vs. docetaxel or irinotecan.
Why It Matters
CLDN18.2 is the target of Astellas's zolbetuximab (Vyloy, approved 2024) as a naked antibody. ATG-022 layers a cytotoxic payload onto the same target; testing whether the ADC format outperforms the naked antibody. If positive, CLDN18.2 becomes the second solid tumor target (after HER2) validated for ADC intensification.
Verified sources
DN022150 Monotherapy vs. Investigator's Choice in Previously Treated KRAS G12D-Mutant Pancreatic Cancer
Phase 3 · Oncology; KRAS G12D pancreatic cancer
Timeline
Start September 2026; Primary completion July 2028
Mechanism
DN022150 is a KRAS G12D inhibitor tested as monotherapy in previously treated advanced pancreatic ductal adenocarcinoma. KRAS G12D is the most common oncogenic KRAS mutation in PDAC (~40% of cases).
Why It Matters
KRAS G12C inhibitors (adagrasib, sotorasib) opened the door; KRAS G12D was the next frontier. Revolution Medicines (RMC-6236), Mirati/BMS, and multiple Chinese biotechs (including Kvvit) are racing to be first. DN022150 is one of the leading Chinese contenders reaching Phase 3 in pancreatic. Positive readout in the historically undruggable KRAS G12D+ PDAC population would establish the first genotype-directed pancreatic cancer therapy.
Verified sources
Vaccines & Cardiometabolic
5 trialsmRNA-Based Seasonal Influenza Vaccine vs. Licensed Influenza Vaccine in Adults ≥65
Phase 3 · Vaccines; mRNA seasonal influenza (65+); MEGA-SCALE
Timeline
Start September 2, 2026; Primary completion June 2028
Mechanism
Randomized comparison of GSK's mRNA-based seasonal influenza vaccine vs. a licensed comparator (standard high-dose or adjuvanted) in adults ≥65 for clinical efficacy against laboratory-confirmed influenza illness.
Why It Matters
The largest mRNA-vaccine efficacy trial ever registered. Moderna's mRNA-1010 and Pfizer's mRNA flu program have hit mixed results; GSK's 54,000-patient head-to-head against licensed vaccines in older adults is designed to be the definitive readout for whether mRNA meaningfully outperforms current flu vaccine technology. Franchise implications extend far beyond flu; establishes the platform's competitive position vs. protein-subunit vaccines across all future respiratory targets.
Verified sources
Balcinrenone/Dapagliflozin vs. Dapagliflozin for Renal + CV Outcomes in Advanced CKD
Phase 3 · Cardiometabolic; CKD 3b/4; MEGA-SCALE
Timeline
Start September 1, 2026; Primary completion July 2030
Mechanism
Fixed-dose combination of balcinrenone (AZ's non-steroidal mineralocorticoid receptor antagonist) plus dapagliflozin (Farxiga, approved SGLT2 inhibitor) vs. dapagliflozin monotherapy in patients with Stage 3b to 4 CKD.
Why It Matters
First Phase 3 of a fixed-dose nsMRA + SGLT2i combination; anticipating the paradigm that FIDELIO-DKD/FIGARO-DKD (finerenone) established for MRA benefit on top of SGLT2i in CKD. If positive, AZ combines two of the highest-signal drug classes in cardiorenal medicine into a single pill; driving compliance and shifting the CKD franchise economics.
Verified sources
Orforglipron vs. Placebo in Overweight Individuals at Risk of Obesity-Related Complications or Class 1 Obesity Progression
Phase 3 · Cardiometabolic; overweight (pre-obesity); MEGA-SCALE
Timeline
Start September 2026; Primary completion August 2029
Mechanism
Once-daily oral orforglipron (Lilly's oral non-peptide GLP-1 receptor agonist) tested in adults with overweight (BMI 25 to 29.9) plus prediabetes, prehypertension, or abdominal obesity; the pre-Class 1 population.
Why It Matters
First large Phase 3 of a GLP-1 in the overweight (pre-obesity) population for prevention of progression to Class 1 obesity. If Lilly gets a label in overweight, the total addressable metabolic market expands from ~40% of US adults (obesity) to ~70% (overweight + obesity). Reframes the category from disease treatment to lifelong risk reduction.
Verified sources
Once-Daily Oral Orforglipron vs. Once-Weekly Dulaglutide in Pediatric T2D (Age 10 to <18)
Phase 3 · Cardiometabolic; pediatric T2D (age 10 to 18)
Timeline
Start September 2026; Primary completion March 2030
Mechanism
Head-to-head Phase 3 of Lilly's oral orforglipron vs. Lilly's own once-weekly injectable dulaglutide (Trulicity) in pediatric patients age 10 to <18 with type 2 diabetes.
Why It Matters
Pediatric T2D is a rapidly growing indication with limited treatment options; metformin, insulin, extendin (Bydureon in age 10+), and dulaglutide (added 2022). An oral daily option would dramatically simplify pediatric T2D management vs. weekly injections. If positive, orforglipron becomes the first oral GLP-1 approved for pediatric T2D.
Verified sources
Tirzepatide Once Weekly vs. Placebo in Pediatric Participants Aged 6 to <12 With Obesity
Phase 3 · Cardiometabolic; pediatric obesity (age 6 to 12)
Timeline
Start September 2026; Primary completion December 2029
Mechanism
Tirzepatide (Zepbound/Mounjaro, Lilly's approved GIP/GLP-1 dual agonist) in pediatric obesity age 6 to <12. Extends age eligibility 4 years below the current pediatric obesity approvals for GLP-1 agents (semaglutide, tirzepatide are approved from age 12).
Why It Matters
Extending incretin therapy into 6-to-under-12 pediatric obesity is a controversial and high-signal move. The CDC estimates 15% of US children age 6 to 11 have obesity. If positive and approved, tirzepatide becomes the first incretin for pre-adolescent obesity; a market and pediatric guideline shift with significant policy implications.
Verified sources
Immunology & Respiratory
3 trialsLunsekimig Long-Term Safety and Efficacy Extension in COPD (Including Inhaled Corticosteroid Withdrawal)
Phase 3 · Respiratory; COPD long-term extension; MEGA-SCALE
Timeline
Start September 14, 2026; Primary completion July 2031
Mechanism
Long-term extension of Sanofi's lunsekimig (IL-13/TSLP bispecific nanobody) in COPD patients who completed the parent EFC18243 or EFC18244 studies. Includes inhaled corticosteroid withdrawal to test whether lunsekimig can replace ICS therapy entirely.
Why It Matters
The ICS withdrawal arm is the key strategic feature. If lunsekimig lets COPD patients drop inhaled steroids without exacerbations, Sanofi delivers a corticosteroid-sparing regimen; a major benefit in a population with high steroid-related comorbidities. Competes directly with GSK's felcorekibart PERSIST COPD program (Edition 16) in the Type 2 COPD franchise fight.
Verified sources
ROSY-S · Anifrolumab (Saphnelo) Rollover for Continued Treatment in SLE, Cutaneous Lupus, Systemic Sclerosis, and Myositis
Phase 3 · Immunology; Anifrolumab rollover (SLE, SSc, myositis); MEGA-SCALE
Timeline
Start September 1, 2026; Primary completion December 2032
Mechanism
Long-term rollover Phase 3 of anifrolumab (Saphnelo, AZ's approved anti-IFNAR1 mAb for SLE) for patients continuing to benefit from prior anifrolumab studies. Includes cutaneous lupus, systemic sclerosis, and myositis populations; extending Saphnelo beyond the approved SLE label.
Why It Matters
Anifrolumab is currently approved only in SLE. ROSY-S serves as the vehicle for building long-term evidence in adjacent Type I interferon-driven diseases; cutaneous lupus, systemic sclerosis, and dermatomyositis. If AZ builds enough exposure data across 1,072 patients in these indications, expanded label filings follow. Extends the Saphnelo franchise from a single indication to a Type I IFN platform.
Verified sources
Adimanebart IV in Adult and Pediatric DOK7-, MUSK-, AGRN-, or LRP4-Congenital Myasthenic Syndrome
Phase 3 · Immunology; congenital myasthenic syndrome (first pivotal)
Timeline
Start September 2026; Primary completion October 2030
Mechanism
Adimanebart (argenx's investigational MuSK agonist antibody) tested in adult and pediatric patients with congenital myasthenic syndromes (CMS) caused by mutations in DOK7, MUSK, AGRN, or LRP4; the neuromuscular junction (NMJ) building-block genes.
Why It Matters
First Phase 3 in congenital myasthenic syndrome; an ultra-rare group of inherited NMJ disorders. Patients rely on symptomatic pyridostigmine + salbutamol/ephedrine off-label; there's no approved therapy. argenx extends its NMJ franchise (efgartigimod, Vyvgart) into congenital disease with a first-in-class agonist approach. Positive readout would establish the first approved CMS therapy and a new franchise pillar for argenx.
Verified sources
Advanced Modalities; Gene & Cell Editing
2 trialsCTX112 · Allogeneic CRISPR-Cas9-Engineered Anti-CD19 T Cells in Refractory Neurologic Autoimmune Disease
Phase 1/2 · Adv. Modalities; allo CRISPR CD19 CAR-T for neuro autoimmune
Timeline
Start September 15, 2026; Primary completion December 2029
Mechanism
CTX112 is CRISPR Therapeutics' allogeneic (off-the-shelf) CD19-directed CAR-T therapy engineered using CRISPR-Cas9 to disrupt TCR and MHC-I expression, enabling universal-donor administration. Tested in progressive MS, neuromyelitis optica, MOG-associated disease, autoimmune encephalitis, and stiff-person syndrome.
Why It Matters
First allogeneic CD19 CAR-T Phase 1/2 in neurologic autoimmune disease; a step beyond the ex vivo autologous CD19 CAR-T successes in lupus and myasthenia gravis. Combined with Edition 16's Myeloid Therapeutics in vivo CD19 CAR-T (CRT-402 for lupus/scleroderma/myositis), autoimmune CAR-T is now advancing on both the in vivo and allogeneic-ex vivo paths simultaneously. CRISPR Therapeutics's second CRISPR-based CV entry in three editions (after CTX340 hypertension in Edition 15).
Verified sources
PM577a · Prime Editing for the ATP7B p.H1069Q Mutation in Wilson Disease
Phase 1/2 · Adv. Modalities; Prime Editing (Wilson Disease)
Timeline
Start September 2026; Primary completion November 2028
Mechanism
PM577a is Prime Medicine's Prime Editing therapeutic targeting the p.H1069Q mutation in the ATP7B gene; the most common Wilson Disease-causing mutation (~40% of Northern European cases). Delivered as a single infusion to correct the mutation in hepatocytes and restore copper transport.
Why It Matters
First clinical Phase 1/2 of a Prime Editing therapeutic in any indication. Prime Editing was the third major CRISPR generation (after base editing); enables precise nucleotide substitution without creating double-strand DNA breaks. If PM577a shows safe hepatic editing and clinical benefit in Wilson Disease, Prime Editing joins base editing (Verve, Beam) and CRISPR-Cas9 (CRISPR Therapeutics, Intellia) as validated clinical platforms.
Verified sources
Signal Convergence
Five patterns across the September 1 to 15 window
1. The largest mRNA-vaccine efficacy trial ever registered
GSK's 54,000-patient Phase 3 of mRNA flu vaccine vs. licensed influenza vaccine in adults 65+ is the definitive readout for whether mRNA meaningfully outperforms legacy flu vaccine technology. Franchise implications extend far beyond flu; sets the mRNA-vs-protein-subunit precedent for all future respiratory vaccine targets.
2. Lilly extends metabolic disease across three new age brackets
Orforglipron in overweight adults (2,001 pts, pre-obesity), orforglipron in pediatric T2D age 10 to 18 (170 pts), and tirzepatide in pediatric obesity age 6 to 12 (150 pts). Combined with Amgen MariTide extensions (Ed 14), AbbVie ABBV-295 (Ed 15), and AZ SELENE program (Ed 16), the obesity/T2D category expands from adult disease treatment to lifelong risk reduction across pediatric-through-geriatric populations.
3. Gene editing platforms diversify beyond CRISPR-Cas9
Prime Medicine opens its first Prime Editing Phase 1/2 in Wilson Disease. CRISPR Therapeutics opens CTX112 (allogeneic CRISPR-Cas9 CD19 CAR-T for neurologic autoimmune); its second CV-adjacent CRISPR clinical entry in three editions after CTX340 hypertension (Ed 15). Combined with Ed 16's Myeloid Therapeutics in vivo CAR-T, the editing modality landscape now spans in vivo LNP-Cas9, in vivo CAR-T, allogeneic Cas9-engineered CAR-T, and Prime Editing; all in simultaneous clinical development.
4. BiTE-on-BiTE combinations reach Phase 3
TiTan tests Teclistamab + Talquetamab (dual BCMA+GPRC5D bispecifics) vs. Daratumumab + Lenalidomide in MRD+ NDMM post-ASCT. First randomized Phase 3 of two Janssen bispecifics in combination. Validates dual-BiTE consolidation as a strategy across hematologic malignancies.
5. First-in-class targets reach Phase 3 in previously undruggable disease
Incyte's INCA033989 (anti-mutant-CALR mAb) in ET is the first Phase 3 of a mutant-CALR-targeted therapy; CALR was undruggable until this. argenx's adimanebart in DOK7/MUSK/AGRN/LRP4 CMS is the first Phase 3 in congenital myasthenic syndrome. First-in-indication pivotals continue to arrive at an unprecedented pace.
Underlying truth: clinical development is expanding into age brackets, mechanisms, and disease entities that were closed even 12 months ago. Pre-obesity. Pediatric-under-12 incretins. Mutant CALR. Congenital myasthenic syndromes. Prime Editing. Allogeneic CAR-T for neuro autoimmune. The definition of "addressable market" is being rewritten in real time.
Continue Tracking
Trial Watch is Kitsa's clinical intelligence layer. Edition 18 (September 16 to 30, 2026) drops on September 30.
On Verification
Final source recheck completed for Edition 17 on September 15, 2026. Each trial is linked to its exact ClinicalTrials.gov record plus one exact trial-specific secondary page that resolves to the same NCT/study. WHO ICTRP links, generic sponsor homepages, broad trial-search portals, and "search this term" notes have been removed. Secondary links that could not be directly confirmed in the final recheck were replaced with currently live exact-study pages. All 15 listed trials retain registry-derived start dates within September 1 to 15, 2026.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.